Purpose To investigate the relationship between retinal sensitivity (RS) assessed by microperimetry (MP) and retinal structural changes in patients with resolved central serous chorioretinopathy (CSC). Methods Spectral domain optical coherence tomography (OCT) examination and MP tests were performed in patients with resolved CSC. Point-to-point correlation was performed between RS and corresponding retinal structural changes using Pearson's correlation analysis. In addition, in a 1-mm zone in the central fovea, a correlation was calculated between the mean RS and the mean central retinal thickness (CRT). Results Eighty-four eyes were analyzed. The total number of MP test points was 1092 (84 eyes  13 points). The mean RS and retinal point thickness (RPT) of all test points were 13.53±3.84 dB and 208.6±48.0 mm, respectively. The RS and RPT were significantly decreased in the test points with loss of the ellipsoid portion of the inner segments (EPIS) (Po0.0001). Within the 1-mm foveal center zone, there was a significant correlation between mean RS and mean CRT (r ¼ 0.432, Po0.0001) and between RS and the corresponding RPT (r ¼ 0.339, Po0.0001). Conclusion RS was dependent on the status of the EPIS in patients with resolved CSC. The correlation between mean RS and mean CRT was compatible with the point-topoint correlation between RS and the corresponding RPT.
ABSTRACT. We conducted a case-control study to investigate the association between PAR1 gene polymorphisms and the development of chronic obstructive pulmonary disease (COPD). A total of 270 patients with COPD and 270 control subjects were consecutively recruited between March 2012 and March 2014. A polymerase chain reaction restriction fragment length polymorphism assay was used to assess the polymorphisms PAR1 IVS-14 A/T rs168753 and -506 I/D rs11267092. The frequency of the AA genotype in PAR1 IVS-14 A/T rs168753 was significantly higher than in the controls (χ 2 = 7.23, P = 0.03). By logistic regression analysis, we found that the AA genotype of PAR1 IVS-14 A/T rs168753 was associated with increased risk of COPD compared with the GG genotype. The adjusted OR (95%CI) was 2.00 (1.15-3.50) for the AA genotype. In conclusion, we found that the PAR1 IVS-14 A/T rs168753 polymorphism was associated with the development of COPD.
Purpose The tendon width of the lateral rectus muscle is known to be a useful indicator for estimation of the effect of lateral rectus recession in intermittent exotropia. This study was conducted to investigate whether the tendon width of the lateral rectus would differ according to different age groups. Patients and methods We studied 133 patients ranging from 0 to 51 years of age who had undergone bilateral lateral rectus (BLR) recession for the basic type of intermittent exotropia. A total of 133 patients were divided into four groups; 16 patients who were younger than 2 years old (group 1), 20 patients who were 2-5 years old (group 2), 75 patients who were 5-13 years old (group 3), and 22 patients who were older than 13 years (group 4). Under general anesthesia and before dissection of the muscle tendon from the sclera, the tendon width of the lateral rectus of both eyes near insertion was measured with calipers. Results The tendon width of each group was as follows: in group 1, 7.84 ± 0.35 mm in the right eye and 7.66 ± 0.44 mm in the left eye; in group 2, 7.70 ± 0.50 mm and 7.65 ± 0.52; in group 3 8.11 ± 0.36, 7.95 ± 0.48. In group 4, measurements were 8.14±0.49 mm and 8.05±0.38 mm, respectively. The difference of tendon width in both eyes was statistically significant in all four groups (Po0.01) and the tendon widths of group 1 and 2 were narrower than that of group 3 and 4. Conclusion Measurement of tendon width of the lateral rectus muscle for prediction of the effect in intermittent exotropia should be applied in patients Z5 years of age.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.